The FDA warned an asthma drug could induce despair. Many were never told - Video
Overview
In 2020, the Food and Drug Administration (FDA) issued a stark warning about the asthma and allergy drug Singulair, indicating potential side effects such as aggression and suicidal thoughts. However, the warning had limited impact, as the drug was still prescribed to 12 million people in the United States in 2022. Children, who face higher risks, continued to use the drug, with 1.6 million prescriptions. The FDA's handling of Singulair highlights gaps in addressing side effects from long-approved medications and in effectively warning the public and doctors. Despite issuing a warning label, the FDA did not mandate education for doctors regarding the drug's side effects. Some patients only became aware of the risks through online support groups, emphasizing the need for improved communication about medication risks.
For more news & updates, check out the link given below:
Speakers
